Home / Business and Economy / Europe Innovation Lag: Lundbeck Shifts Focus to US & China
Europe Innovation Lag: Lundbeck Shifts Focus to US & China
13 Mar
Summary
- Lundbeck prioritizes US and China for investments over Europe.
- Europe faces pressure to better incentivize pharmaceutical innovation.
- Drugmaker has $2-3 billion available for mergers and acquisitions.
H. Lundbeck A/S, a Danish pharmaceutical company, is strategically redirecting its capital investments towards the United States and China, citing a perceived lack of innovation incentives in Europe. CEO Charl van Zyl highlighted the significant recognition of innovation in the US, along with China's advancements in technology and AI-driven discovery, as key drivers for this shift. Europe is experiencing increasing pressure from drugmakers to enhance financial rewards for innovation and increase payments for new medicines.
While currently facing generic competition outside the US for its schizophrenia and bipolar disorder treatment, Abilify Maintena, Lundbeck is actively seeking smaller deals to expand its drug pipeline. The company has allocated between $2 billion and $3 billion for mergers and acquisitions. Lundbeck's focus remains on making its medicines accessible to as many patients as possible, with a new product anticipated for market in 2028 or later.
